Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia

References

• Brunning RD. Classification of acute leukemias. Semin Diagn Pathol. 2003;20(3):142–153.
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Fathi A, et al. NCCN guidelines insights: acute lymphoblastic leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017;15(9):1091–1102.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Q-F, Wu D-P, et al. Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. Sci China Life Sci. 2020;63(10):1552–1564.
   Web of Science ®Google Scholar
• Su XH, Yao JF, Zhang GX, et al. Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors. Zhonghua Xue Ye Xue Za Zhi. 2017;38(12):1024–1030.
   PubMedGoogle Scholar
• Yoo SH, Koh Y, Kim D-Y, et al. Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. Ann Hematol. 2017;96(4):605–615.
   PubMed Web of Science ®Google Scholar
• Yalniz FF, Patel KP, Bashir Q, et al. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020;126(10):2183–2192.
   PubMed Web of Science ®Google Scholar
• Juul-Dam KL, Ommen HB, Nyvold CG, et al. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. Br J Haematol. 2020;190(2):198–208.
   Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, Multicenter Standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• Inagaki J, Fukano R, Noguchi M, et al. Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children. Pediatr Blood Cancer. 2015;62(4):674–679.
   PubMed Web of Science ®Google Scholar
• Bourlon C, Lacayo-Leñero D, Inclán-Alarcón SI, et al. Hematopoietic stem cell transplantation for adult Philadelphia-negative acute lymphoblastic leukemia in the first complete remission in the era of minimal residual disease. Curr Oncol Rep. 2018;20(4):36.
   PubMed Web of Science ®Google Scholar
• Rustad EH, Boyle EM. Monitoring minimal residual disease in the bone marrow using next generation sequencing. Best Pract Res Clin Haematol. 2020;33(1):101149.
   PubMed Web of Science ®Google Scholar
• Rastogi P, Sachdeva M. Flow cytometric minimal residual disease analysis in acute leukemia: current status. Indian J Hematol Blood Transfus. 2020;36(1):3–15.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease With clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang Z, Ruan G, et al. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol. 2018;97(6):967–975.
   PubMed Web of Science ®Google Scholar
• Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002;16(9):1668–1672.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu L, Chen J-B, et al. [Clinical significance of minimal residual disease monitoring by multi-parameter flow cytometry before allogeneic hematopoietic stem cell transplantation for prognosis of acute leukemia patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(1):262–266.
   PubMedGoogle Scholar
• Bader P, Salzmann-Manrique E, Balduzzi A, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019;3(21):3393–3405.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Duarte R, Snowden JA, et al. Pre-transplantation Risks and transplant-techniques in haematopoietic stem cell transplantation for acute leukaemia. EClinicalMedicine. 2019;15:33–41.
   PubMedGoogle Scholar
• Zhao H, Wei J, Wei G, et al. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. J Hematol Oncol. 2020;13(1):42.
   PubMed Web of Science ®Google Scholar
• Salhotra A, Yang D, Mokhtari S, et al. Outcomes of allogeneic hematopoietic cell transplantation after Salvage Therapy with Blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020;26(6):1084–1090.
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia J, Serrano J, Serrano-Lopez J, et al. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL. Bone Marrow Transplant. 2013;48(3):396–402.
   PubMed Web of Science ®Google Scholar
• Lovisa F, Zecca M, Rossi B, et al. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol. 2018;180(5):680–693.
   PubMed Web of Science ®Google Scholar